October 22, 2016 2:02 PM ET

Life Sciences Tools and Services

Company Overview of Hadasit Medical Research Services & Development Ltd.

Company Overview

Hadasit Medical Research Services & Development Ltd., a technology transfer company, identifies, protects, nurtures, and commercializes inventions developed in Hadassah. The company assists physicians and researchers in defining the medical unmet needs, aligning the inventions and supporting research with regulatory and market expectations, and raising funds to support proof-of-concept development. It also offers pre-clinical services, including cell biology clinical diagnostics, consultations and counseling, disease models and experimental surgery, drug discovery, genetics, GMP production, imaging, neurology, pharmacology, vaccines and immunotherapy, and virology and immunology. In addition...

Jerusalem BioPark

Hadassah Ein Kerem

POB 12000

Jerusalem,  91120


Founded in 1986


972 2 677 9424


972 2 643 7712

Key Executives for Hadasit Medical Research Services & Development Ltd.

Chief Executive Officer
Vice President of Finance & Contracts
General Counsel
Executive Officer
Compensation as of Fiscal Year 2016.

Hadasit Medical Research Services & Development Ltd. Key Developments

BiolineRx Signs In-Licensing Deal for Liver Fibrosis Treatment with Hadasit

BioLineRx has signed an exclusive worldwide agreement with Hadasit, for the in-licensing of drug candidate BL-1210 to treat liver fibrosis. It is the first project to be in-licensed under the framework of the company's strategic collaboration with Novartis Pharma AG for the screening and development of novel drug candidates.

Immune Pharmaceuticals Inc. and Hadasit Files Provisional Patent on the Oral Use of Anti-Eotaxin Monoclonal Antibodies

Immune Pharmaceuticals Inc. and Hadasit announced that they together filed a provisional patent on the oral use of anti-eotaxin monoclonal antibodies, including Immune's bertilimumab, for the treatment of inflammatory gastro-intestinal (GI) and liver diseases. Immune signed a licensing agreement with Hadasit in conjunction with the provisional patent filing. Immune is currently conducting a double blind placebo controlled phase IIA clinical trial in Ulcerative Colitis, with parenteral bertilimumab. Immune is currently collaborating with Professor Arun Sanyal, former President of the American Liver Association, and Professor of Medicine at Virginia Commonwealth University (VCU) Medical Center to obtain additional insights on the potential role of eotaxin in NASH. Phase II clinical trials in patients with NASH are planned to follow these collaborative studies. Eotaxin-1, a specific chemokine, plays a role in both innate and adaptive immune responses and modulates the cross-talk between key cells involved in inflammation. Bertilimumab is a first-in-class monoclonal antibody that blocks eotaxin-1, is designed for personalized therapy in inflammatory conditions mediated by high eotaxin-1 levels, among which are Crohn's Disease and Ulcerative Colitis, NASH, and primary sclerosing cholangitis (PSC). Alleviation of insulin resistance is also associated with decreased eotaxin-1.

ISA Scientific, Inc., Yissum Research Development Company Ltd., Hadasit Ltd. and the Kennedy Trust for Rheumatology Research to Collaborate on Treating Diabetes and Other Serious Health Conditions with Cannabidiol

Yissum Research Development Company Ltd. (Yissum), Hadasit Ltd. (Hadasit), and the Kennedy Trust for Rheumatology Research (KIR) announced that they have signed an exclusive worldwide licensing and collaboration agreement with ISA Scientific Inc. for using the non-psychoactive cannabinoid, cannabidiol (CBD), to treat serious medical conditions, including diabetes, inflammatory diseases (like arthritis, atherosclerosis and ulcerative colitis) and cardiovascular disorders.

Similar Private Companies By Industry

Company Name Region
Alfa Rhythm Ltd. Middle East/Africa
AllergyFight Ltd. Middle East/Africa
Arcuro Medical Ltd. Middle East/Africa
Axonix Ltd. Middle East/Africa
Clal Life Sciences L.P. Middle East/Africa

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Hadasit Medical Research Services & Development Ltd., please visit www.hadasit.co.il. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.